Phase II Study to Evaluate the Role of Bortezomib in the Management of Relapsed Acute Promyelocytic Leukemia

Trial Profile

Phase II Study to Evaluate the Role of Bortezomib in the Management of Relapsed Acute Promyelocytic Leukemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2013

At a glance

  • Drugs Bortezomib (Primary) ; Arsenic trioxide
  • Indications Acute promyelocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top